logo-loader
viewInvitrocue Ltd

Invitrocue leads market with disruptive technology and personalised oncology solutions

Invitrocue Ltd (ASX:IVQ) chief executive officer Steven Fang speaks to Proactive Investors about the oncology-focused company's development of cancer treatments by testing specific drugs on laboratory-controlled micro-tumours. 
 
"We've been able to take some of these really innovative, disruptive technologies and apply it to the space of being able to create these micro-tumours," says Fang.
 
He continues, "That allows us to test the response of these cancer cells against those specific drugs.
 
"But it's always done individualised - this whole area of personalised oncology is now coming to market."

Quick facts: Invitrocue Ltd

Price: 0.06 AUD

ASX:IVQ
Market: ASX
Market Cap: $31.52 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Invitrocue Ltd named herein, including the promotion by the Company of Invitrocue Ltd in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Open Orphan confirms hVIVO deal is done

Cathal Friel, CEO of Open Orphan announces that the hVIVO deal is finally in the bag and tells Proactive London what the timeline for shareholders now looks like. News here on the Genomic Database and how Friel expects hVIVO to make a profit. Confirmation too on the slight musical chairs within...

3 days, 19 hours ago

2 min read